Top segments and regional performance

Last year, the company generated ‪76.20 M‬ USD, the most of which — ‪76.20 M‬ USD — came from its top-performing segment, Probody Therapeutics, compared to ‪138.10 M‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪76.20 M‬ USD last year, with ‪138.10 M‬ USD the year before.